The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Orthofix International's revenues will wane -12.5% and EPS will decrease -53.8%.
The average estimate for revenue is $104.6 million. On the bottom line, the average EPS estimate is $0.36.
Last quarter, Orthofix International chalked up revenue of $100.3 million. GAAP reported sales were 14% lower than the prior-year quarter's $116.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.23. GAAP EPS of $0.11 for Q1 were 83% lower than the prior-year quarter's $0.63 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 77.4%, 370 basis points worse than the prior-year quarter. Operating margin was 4.0%, much worse than the prior-year quarter. Net margin was 2.1%, 830 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $419.0 million. The average EPS estimate is $1.53.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 125 members out of 133 rating the stock outperform, and eight members rating it underperform. Among 36 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Orthofix International a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Orthofix International is hold, with an average price target of $46.29.
Is Orthofix International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Orthofix International to My Watchlist.